Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
Scalzulli E, Caocci G, Efficace F, Rizzo L, Colafigli G, Di Prima A, Pepe S, Fegatelli DA, Carmosino I, Diverio D, Latagliata R, La Nasa G, Martelli M, Foà R, Breccia M. Scalzulli E, et al. Among authors: di prima a. Ann Hematol. 2021 May;100(5):1213-1219. doi: 10.1007/s00277-021-04477-0. Epub 2021 Mar 7. Ann Hematol. 2021. PMID: 33677654
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?
Colafigli G, Scalzulli E, Di Prima A, Pepe S, Loglisci MG, Diverio D, Martelli M, Foà R, Breccia M. Colafigli G, et al. Among authors: di prima a. Crit Rev Oncol Hematol. 2021 Jan;157:103163. doi: 10.1016/j.critrevonc.2020.103163. Epub 2020 Nov 12. Crit Rev Oncol Hematol. 2021. PMID: 33246263 Review.
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up.
Scalzulli E, Colafigli G, Pepe S, De Luca G, Di Prima A, Efficace F, Diverio D, Latagliata R, Martelli M, Foà R, Breccia M. Scalzulli E, et al. Among authors: di prima a. Leuk Lymphoma. 2021 Apr;62(4):1026-1027. doi: 10.1080/10428194.2020.1808205. Epub 2020 Aug 16. Leuk Lymphoma. 2021. PMID: 32799601 No abstract available.
The advantages and risks of ruxolitinib for the treatment of polycythemia vera.
Colafigli G, Scalzulli E, Pepe S, Di Prima A, Efficace F, Martelli M, Foà R, Breccia M. Colafigli G, et al. Among authors: di prima a. Expert Rev Hematol. 2020 Oct;13(10):1067-1072. doi: 10.1080/17474086.2020.1816819. Epub 2020 Sep 11. Expert Rev Hematol. 2020. PMID: 32873088 Review.
59 results